PCRX logo

Pacira BioSciences, Inc. (PCRX) EBITDA

annual EBITDA:

$176.36M+$13.46M(+8.26%)
December 31, 2024

Summary

  • As of today (September 17, 2025), PCRX annual EBITDA is $176.36 million, with the most recent change of +$13.46 million (+8.26%) on December 31, 2024.
  • During the last 3 years, PCRX annual EBITDA has risen by +$14.98 million (+9.28%).
  • PCRX annual EBITDA is now at all-time high.

Performance

PCRX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCRXincome statement metrics

quarterly EBITDA:

$29.24M-$4.37M(-13.00%)
June 30, 2025

Summary

  • As of today (September 17, 2025), PCRX quarterly EBITDA is $29.24 million, with the most recent change of -$4.37 million (-13.00%) on June 30, 2025.
  • Over the past year, PCRX quarterly EBITDA has dropped by -$29.33 million (-50.07%).
  • PCRX quarterly EBITDA is now -51.33% below its all-time high of $60.08 million, reached on June 30, 2023.

Performance

PCRX quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCRXincome statement metrics

TTM EBITDA:

-$1.30M-$29.33M(-104.64%)
June 30, 2025

Summary

  • As of today (September 17, 2025), PCRX TTM EBITDA is -$1.30 million, with the most recent change of -$29.33 million (-104.64%) on June 30, 2025.
  • Over the past year, PCRX TTM EBITDA has dropped by -$187.29 million (-100.70%).
  • PCRX TTM EBITDA is now -100.69% below its all-time high of $187.51 million, reached on March 31, 2024.

Performance

PCRX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCRXincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

PCRX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+8.3%-50.1%-100.7%
3 y3 years+9.3%-42.5%-100.9%
5 y5 years+219.0%+987.0%-103.8%

PCRX EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+9.3%-51.3%+125.5%-100.7%at low
5 y5-yearat high+219.0%-51.3%+125.5%-100.7%at low
alltimeall timeat high+470.9%-51.3%+125.5%-100.7%+97.8%

PCRX EBITDA History

DateAnnualQuarterlyTTM
Jun 2025
-
$29.24M(-13.0%)
-$1.30M(-104.6%)
Mar 2025
-
$33.61M(-33.6%)
$28.03M(-3.8%)
Dec 2024
$176.36M(+8.3%)
$50.60M(-144.1%)
$29.12M(-12.9%)
Sep 2024
-
-$114.75M(-295.9%)
$33.42M(-82.0%)
Jun 2024
-
$58.57M(+68.8%)
$185.99M(-0.8%)
Mar 2024
-
$34.70M(-36.8%)
$187.51M(+21.3%)
Dec 2023
$162.90M(+0.3%)
$54.91M(+45.2%)
$154.59M(+27.1%)
Sep 2023
-
$37.81M(-37.1%)
$121.61M(+5.7%)
Jun 2023
-
$60.08M(+3275.4%)
$115.02M(+8.7%)
Mar 2023
-
$1.78M(-91.9%)
$105.77M(-24.7%)
Dec 2022
$162.43M(+0.6%)
$21.93M(-29.7%)
$140.38M(+4.0%)
Sep 2022
-
$31.22M(-38.6%)
$134.96M(-3.9%)
Jun 2022
-
$50.83M(+39.7%)
$140.37M(+11.0%)
Mar 2022
-
$36.39M(+120.3%)
$126.45M(+11.0%)
Dec 2021
$161.38M(+126.0%)
$16.52M(-54.9%)
$113.95M(-6.3%)
Sep 2021
-
$36.63M(-0.8%)
$121.61M(+18.4%)
Jun 2021
-
$36.91M(+54.5%)
$102.67M(+50.0%)
Mar 2021
-
$23.89M(-1.2%)
$68.45M(+7.8%)
Dec 2020
$71.42M(+29.2%)
$24.17M(+36.6%)
$63.51M(+36.7%)
Sep 2020
-
$17.69M(+557.6%)
$46.45M(+36.4%)
Jun 2020
-
$2.69M(-85.8%)
$34.06M(-21.2%)
Mar 2020
-
$18.96M(+166.6%)
$43.23M(+40.6%)
Dec 2019
$55.29M(+46.5%)
$7.11M(+34.2%)
$30.75M(-25.6%)
Sep 2019
-
$5.30M(-55.3%)
$41.35M(-6.2%)
Jun 2019
-
$11.86M(+83.2%)
$44.08M(+3.3%)
Mar 2019
-
$6.48M(-63.4%)
$42.66M(+29.1%)
Dec 2018
$37.74M(+4268.5%)
$17.71M(+120.5%)
$33.06M(+16.6%)
Sep 2018
-
$8.03M(-23.0%)
$28.34M(+35.9%)
Jun 2018
-
$10.44M(-433.7%)
$20.85M(-2861.6%)
Mar 2018
-
-$3.13M(-124.1%)
-$755.00K(-93.7%)
Dec 2017
$864.00K
$13.00M(+2293.6%)
-$11.97M(-50.1%)
Sep 2017
-
$543.00K(-104.9%)
-$24.00M(-42.8%)
Jun 2017
-
-$11.17M(-22.1%)
-$41.94M(+23.8%)
DateAnnualQuarterlyTTM
Mar 2017
-
-$14.34M(-1575.7%)
-$33.88M(+83.4%)
Dec 2016
-$12.01M(-157.4%)
$972.00K(-105.6%)
-$18.48M(+7.4%)
Sep 2016
-
-$17.40M(+460.6%)
-$17.21M(-311.2%)
Jun 2016
-
-$3.10M(-393.4%)
$8.14M(-48.7%)
Mar 2016
-
$1.06M(-52.8%)
$15.87M(-23.4%)
Dec 2015
$20.93M(+329.8%)
$2.24M(-71.8%)
$20.70M(-28.7%)
Sep 2015
-
$7.95M(+72.2%)
$29.05M(+29.9%)
Jun 2015
-
$4.62M(-21.7%)
$22.37M(+31.8%)
Mar 2015
-
$5.90M(-44.3%)
$16.97M(+294.1%)
Dec 2014
$4.87M(-110.2%)
$10.58M(+733.3%)
$4.31M(-128.3%)
Sep 2014
-
$1.27M(-262.8%)
-$15.20M(-45.8%)
Jun 2014
-
-$780.00K(-88.5%)
-$28.03M(-26.4%)
Mar 2014
-
-$6.77M(-24.1%)
-$38.08M(-26.7%)
Dec 2013
-$47.54M(+8.9%)
-$8.92M(-22.8%)
-$51.94M(-9.8%)
Sep 2013
-
-$11.56M(+6.7%)
-$57.58M(-3.9%)
Jun 2013
-
-$10.83M(-47.5%)
-$59.89M(+8.0%)
Mar 2013
-
-$20.63M(+41.7%)
-$55.46M(+23.7%)
Dec 2012
-$43.65M(+37.4%)
-$14.56M(+4.9%)
-$44.83M(+3.9%)
Sep 2012
-
-$13.87M(+116.9%)
-$43.15M(+16.7%)
Jun 2012
-
-$6.40M(-36.0%)
-$36.98M(-1.8%)
Mar 2012
-
-$10.00M(-22.4%)
-$37.66M(+11.4%)
Dec 2011
-$31.77M(+73.6%)
-$12.88M(+67.2%)
-$33.79M(+32.2%)
Sep 2011
-
-$7.70M(+8.9%)
-$25.57M(+8.0%)
Jun 2011
-
-$7.08M(+15.4%)
-$23.67M(+11.7%)
Mar 2011
-
-$6.13M(+31.7%)
-$21.19M(+13.6%)
Dec 2010
-$18.30M(-25.0%)
-$4.66M(-19.7%)
-$18.66M(-9.0%)
Sep 2010
-
-$5.80M(+26.3%)
-$20.50M(+3.2%)
Jun 2010
-
-$4.59M(+27.5%)
-$19.86M(+30.1%)
Mar 2010
-
-$3.60M(-44.6%)
-$15.26M(+30.9%)
Dec 2009
-$24.40M(-40.7%)
-$6.50M(+26.1%)
-$11.66M(+126.1%)
Sep 2009
-
-$5.16M
-$5.16M
Dec 2008
-$41.14M(+80.2%)
-
-
Dec 2007
-$22.83M
-
-

FAQ

  • What is Pacira BioSciences, Inc. annual EBITDA?
  • What is the all time high annual EBITDA for Pacira BioSciences, Inc.?
  • What is Pacira BioSciences, Inc. annual EBITDA year-on-year change?
  • What is Pacira BioSciences, Inc. quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Pacira BioSciences, Inc.?
  • What is Pacira BioSciences, Inc. quarterly EBITDA year-on-year change?
  • What is Pacira BioSciences, Inc. TTM EBITDA?
  • What is the all time high TTM EBITDA for Pacira BioSciences, Inc.?
  • What is Pacira BioSciences, Inc. TTM EBITDA year-on-year change?

What is Pacira BioSciences, Inc. annual EBITDA?

The current annual EBITDA of PCRX is $176.36M

What is the all time high annual EBITDA for Pacira BioSciences, Inc.?

Pacira BioSciences, Inc. all-time high annual EBITDA is $176.36M

What is Pacira BioSciences, Inc. annual EBITDA year-on-year change?

Over the past year, PCRX annual EBITDA has changed by +$13.46M (+8.26%)

What is Pacira BioSciences, Inc. quarterly EBITDA?

The current quarterly EBITDA of PCRX is $29.24M

What is the all time high quarterly EBITDA for Pacira BioSciences, Inc.?

Pacira BioSciences, Inc. all-time high quarterly EBITDA is $60.08M

What is Pacira BioSciences, Inc. quarterly EBITDA year-on-year change?

Over the past year, PCRX quarterly EBITDA has changed by -$29.33M (-50.07%)

What is Pacira BioSciences, Inc. TTM EBITDA?

The current TTM EBITDA of PCRX is -$1.30M

What is the all time high TTM EBITDA for Pacira BioSciences, Inc.?

Pacira BioSciences, Inc. all-time high TTM EBITDA is $187.51M

What is Pacira BioSciences, Inc. TTM EBITDA year-on-year change?

Over the past year, PCRX TTM EBITDA has changed by -$187.29M (-100.70%)
On this page